RGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Repligen Corp (RGEN) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has a solid position in its sector and positive long-term growth potential, the current technical indicators, mixed analyst ratings, and recent financial performance suggest a cautious approach. The stock's pre-market price of $115 is near its key support level, but there is no strong signal for immediate upside potential.
The MACD is positive but contracting, RSI is neutral at 27.106, and moving averages are converging. The stock is trading near its S1 support level of 113.682, with resistance at 125.888. There is no clear bullish or bearish signal.
Repligen recently opened a new Training & Innovation Center in Breda, Netherlands, which enhances customer engagement and showcases its bioprocessing technologies. Analysts recognize the company's leadership in continuous manufacturing and its strong mid-term revenue and earnings growth outlook.
The company's Q4 financials showed a significant drop in net income (-139.23% YoY) and EPS (-138.33% YoY), despite an 18.12% increase in revenue. Analyst price targets have been lowered multiple times recently, reflecting cautious sentiment.
In Q4 2025, revenue increased by 18.12% YoY to $197.91M, but net income dropped by -139.23% YoY to $13.29M, and EPS fell by -138.33% YoY to $0.23. Gross margin improved to 52.46%, up 9.45% YoY.
Analysts are mixed. Some maintain a Buy rating with price targets ranging from $140 to $208, citing the company's sector leadership and growth potential. Others have lowered price targets, expressing caution due to macroeconomic risks and sentiment lows in the sector.
